NCT01075464

A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MEGF0444A, a Human IgG1 Antibody, in Combination With Bevacizumab and Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase Ib, open-label, dose-escalation study of MEGF0444A in combination with bevacizumab, and in combination with bevacizumab and paclitaxel as therapy for locally advanced or metastatic solid tumors.

Conditions

• Solid Cancers

Interventions

Type	Name	Description
DRUG	MEGF0444A	Intravenous escalating dose
DRUG	bevacizumab	Intravenous repeating dose
DRUG	paclitaxel	Intravenous repeating dose

Timeline

• Start date: 2010-02-01
• Primary completion: 2013-04-01
• Completion: 2013-04-01
• First posted: 2010-02-25
• Last updated: 2016-11-02

Locations

5 sites across 1 country: United States